User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 11 results.
    • Journal article
    ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
    Laterre, Pierre-François[UCL] Abraham, Edward Janes, Jonathan M Trzaskoma, Benjamin Correll, Nancy L Booth, Frank V (2007) Critical care medicine — Vol. 35, no. 6, p. 1457-63 (2007)
    • Journal article
    A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia.
    Laterre, Pierre-François[UCL] Opal, Steven M Abraham, Edward LaRosa, Steven P Creasey, Abla A Xie, Fang Poole, Lona Wunderink, Richard G (2009) Critical care (London, England) — Vol. 13, no. 2, p. R36 (2009)
    • Journal article
    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre, Pierre-François[UCL] Macias, William Janes, Jonathan Williams, Mark D Nelson, David R Girbes, Amand R J Dhainaut, Jean-François Abraham, Edward (2008) Critical care (London, England) — Vol. 12, no. 5, p. R117 (2008)
    • Journal article
    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre, Pierre-François[UCL] Nelson, David R Macias, William Abraham, Edward Sashegyi, Andreas Williams, Mark D Levy, Mitchell Levi, Marcel Utterback, Barbara Vincent, Jean-Louis (2007) Journal of critical care — Vol. 22, no. 2, p. 142-152 (2007)
    • Journal article
    p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham, Edward Glauser, Michel P Butler, Thomas Garbino, Jorge Gelmont, David Laterre, Pierre-François[UCL] Kudsk, Kenneth Bruining, Hajo A Otto, Charles Tobin, Ellis Zwingelstein, Christian Lesslauer, Werner Leighton, Anton (1997) JAMA : the journal of the American Medical Association — Vol. 277, no.19, p. 1531-1538 (1997)
    • Journal article
    Drotrecogin alfa (activated) in severe sepsis - Reply
    Abraham, Edward Laterre, Pierre-François[UCL] (2006) New England Journal of Medicine — Vol. 354, no. 1, p. 95-96 (2006)
    • Journal article
    Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis: A Randomized Controlled Trial
    OPTIMIST Trial Study Group Abraham, Edward Reinhart, Konrad Opal, Steven Demeyer, Ignace Doig, Christopher López Rodriguez, Angel Beale, Richard Svoboda, Petr Laterre, Pierre-François[UCL] Simon, Stuart Light, Bruce Spapen, Herbert Stone, Judy Seibert, Allan Peckelsen, Claus De Deyne, Cathy Postier, Russell Pettilä, Ville Sprung, Charles L. Artigas, Antonio Percell, Sandra R. Shu, Vincent Zwingelstein, Christian Tobias, Jeffrey Poole, Lona Stolzenbach, James C. Creasey, Abla A. (2003) JAMA : the journal of the American Medical Association — Vol. 290, no. 2, p. 238-247 (2003)
    • Journal article
    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, Edward Laterre, Pierre-François[UCL] Garg, R Levy, H Talwar, D Trzaskoma, Benjamin Francois, B. Guy, JS Bruckmann, M Rea-Neto, A Rossaint, R Perrotin, D Sablotzki, A Arkins, N Utterback, Barbara Macias, WL (2005) New England Journal of Medicine — Vol. 353, no. 13, p. 1332-1341 (2005)
    • Journal article
    Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham, Edward Laterre, Pierre-François[UCL] Garbino, Jorge Pingleton, Susan Butler, Thomas Dugernier, Thierry Margolis, Benjamin Kudsk, Kenneth Zimmerli, Werner Anderson, Paula Reynaert, Marcus Lew, Daniel Lesslauer, Werner Passe, Sharon Cooper, P Burdeska, Alex Modi, Marlene Leighton, Anton Salgo, Miklaus Van der Auwera, Philippe Lenercept Study Group (2001) Critical Care Medicine — Vol. 29, no.3, p. 503-510 (2001)
    • Journal article
    LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A(2), fails to improve clinical outcome for patients with severe sepsis
    Zeiher, BG Steingrub, J Laterre, Pierre-François[UCL] Dmitrienko, A Fukiishi, Y Abraham, Edward (2005) Critical Care Medicine — Vol. 33, no. 8, p. 1741-1748 (2005)
    • Journal article
    Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial
    Opal, Steven Laterre, Pierre-François[UCL] Abraham, Edward Francois, Bruno Wittebole, Xavier[UCL] Lowry, Stephen Dhainaut, Jean-François Warren, Brian Dugernier, Thierry Lopez, Angel Sanchez, Miguel Demeyer, Ignace Jauregui, Luis Lorente, Jose Angel McGee, William Reinhart, Konrad Kljucar, Sascha Souza, Sonia Pribble, John (2004) Critical Care Medicine — Vol. 32, no. 2, p. 332-341 (2004)